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Any discussion of morbid events in diabetes is
going to emphasize cardiovascular and peripheral
vascular problems. Renal disease accounts for a relatively small percentage of the mortality in diabetes;
yet the overall incidence of diabetes mellitus in the
population so greatly exceeds that of the various
types of glomerulonephritis that it has become one of
the most common causes of end-stage renal failure in
this country. It is difficult to assign exact numbers
because the figures in the medical literature vary considerably; however, it is estimated that in the United
States today there are some 10 million people who are
known to be diabetic, who would be found to be
diabetic if tested, or who during the course of their
lives will develop overt diabetes. In autopsy series of
diabetics the prevalence of glomerulosclerosis has
varied from 15% to 82%, with a mean of approximately 30% . This figure will vary depending on how
carefully the kidneys are studied, particularly with
respect to the use of special stains for identifying
glomerulosclerosis; the incidence will also increase
with the proportion ofjuvenile to adult onset diabetics included in the sample. Renal failure is listed as
the cause of death of 6% to 12% of diabetics, and its
incidence is increased seventeenfold in the diabetic
population as compared to the nondiabetic. These
figures are probably applicable to those diabetics who
have many complications and who require referral to
major medical centers for treatment. In terms of the
general diabetic population renal failure is probably
in the range of 1% to 2%. This means that the prevalence of glomerulosclerosis is severalfold higher than
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the prevalence of renal failure, and that simply finding the lesion on biopsy does not indicate that kidney
function itself has been impaired or that there will be
any abnormalities present on urinalysis. As a cause of
end-stage renal failure, diabetes now accounts for
some 15% to 25% of all new cases.
Five years' survival after onset of proteinuria in
diabetics compared to age-matched controls is 65%
opposed to 73% for diabetics who do not develop
proteinuria and 83% for non-diabetics. This does not
mean that these people are dying of renal disease but
that proteinuria heralds increased mortality from all
causes. For juvenile diabetics it is extremely unusual
for proteinuria to develop before 10 years' duration
of the disease or to appear after a protein-free interval greater than 30 years. This means that there are
essentially two populations of juvenile diabetics with
regard to the kidney; those who will have their disease for an unlimited amount of time and never develop renal complications, and those who during the
period between IO and 30 years will note the onset of
renal problems. Finally, in juvenile diabetes mellitus,
azotemia defined as BUN in excess of 30 mg percent
implies end-stage renal failure within three years. An
important point to note is the rarity of a decline in the
glomerular filtration rate before the onset of proteinuria when the cause is diabetic nephropathy. Once
renal failure does ensue it has been calculated that the
glomerular filtration rate falls at an average rate of 1
ml/min each month. With other forms of renal disease, hypertension greatly accelerates the rate of decline in the glomerular filtration rate, an important
point in treatment.
Diabetic nephropathy and microangiopathy are
the main topics under discussion here, but there are
. several other factors which contribute in varying deMCV QUARTERLY 14(3):148-152, 1978
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gree to the progression of renal failure in diabetics.
As there is no therapy for diabetic nephropathy itself,
these other factors assume an importance in line with
their response to treatment. Infection, in particular
pyelonephritis and papillary necrosis, becomes an extremely important factor in the management of the
diabetic. This is true because the autonomic neuropathy that may complicate diabetes favors development
of a neurogenic bladder with high residual urine
which may lead to reflux up the ureter, if the urine is
infected, this reflux will result in secondary pyelonephritis and subsequent papillary necrosis with rapid
loss of renal function. In patients who already have
some type of renal failure, infection, even without
involvement of the renal parenchyma, can result in a
further decline in renal function. One of the theories
that has been advocated to explain this is that certain
types of bacteria can attach themselves to the cells of
the ureter and thereby compromise the peristaltic
action of the ureter which is important in propelling
urine from the renal pelvis into the bladder. This
results in a type of functional obstruction which acts
in the same way as a true obstruction. Treatment of
these patients with antibiotics to eradicate the bacteriuria improves ureteral peristalsis and renal function
as well.
Diabetes is also frequently complicated by hyperlipidemia and hyperuricemia. Uric acid crystals
are a cause of interstitial nephritis, and high uric acid
levels which lead to increased uric acid excretion can
set the stage for uric acid calculi, obstruction, and
subsequent infection. In the evaluation of a diabetic
patient, the potential adverse effect of uric acid
should be considered as this cause of renal failure is
subject to therapy either by alkalinization of the urine
or the use of allopurinol.
A number of cardiovascular problems will also
contribute to the declining glomerular filtration rate.
Hypertension has already been mentioned; this can
accelerate the vascular degenerative changes in the
kidney, leading to nephrosclerosis which in turn can
accelerate the hypertension, creating a cycle which
may be interrupted if the hypertension is successfully
controlled through the careful use of antihypertensive
medication. Another complication of hypertension is
its deleterious effect on the myocardium, leading to
hypertensive cardiomyopathy and congestive heart
failure. This will have an adverse effect on renal function, for as the kidney is damaged secondary to diabetes or other processes and as the vascular disease in
the kidney progresses, autoregulation of blood flow
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in the face of a reduced cardiac output is compromised; thw; low-output congestive heart failure
will result in prerenal azotemia superimposed on the
preexisting ren.il failure. In general, this situation is
handled by the combination of digitalization and diuretics; however, it is worth pointing out the problems associated with excessive use of diuretics in these
patients. They may get too dehydrated, a factor that
will superimpose a prerenal type of azotemia upon
their already preexisting level of renal failure. A compromise has to be worked out in terms of controlling
the symptoms of congestive heart failure without, at
the same time, contributing further to the impairment
of renal function. Diabetics are prone to develop
atherosclerosis, and particularly those patients who
have extremely severe atheromatous disease of the
aorta are subject to embolization to the renal vessels.
This can present as episodic elevations of blood pressure associated with fluctuations in the level of renal
function reflected by BUN and creatinine and accompanied by microscopic or even gross hematuria, depending on how much of the kidney is damaged or
destroyed by infarction.
The actual role of platelets in renal disease is still
largely uncertain, although there is strong circumstantial evidence that platelets may be an important
factor in the decline in renal function not only in
diabetes but in glomerulonephritis as well. However,
the abnormal properties of platelets in diabetes increase the level of suspicion that they have a major
role in the pathogenesis of the renal disease.' In the
laboratory, platelets are studied by incubating them
with various agents such as adenosine diphosphate,
epinephrine, and collagen, which induce aggregation.
The Table shows that the percent aggregation of
platelets in diabetics to all three aggregating agents
exceeds the control sample; moreover, platelets from
diabetics aggregate at a lower concentration of these
agents than the control sample. The reason for this is
not exactly clear, but there is current evidence for a
disturbance of prostaglandin synthesis by the platelets of diabetics. The Figure shows the synthesis of
immunoreactive prostaglandin E following the addition of a precursor of prostaglandin synthesis, arachidonic acid. Diabetic platelets show enhancement of
prostaglandin formation following addition of the
precursor. Thus with the evidence that platelets are
more sticky in the diabetic and aggregate more easily,
the possibility has been raised that within the microcirculation of the kidney, platelet aggregation occurs
and leads to occlusion of the small blood vessels,
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TABLE

Percent Aggregation Four Minutes After the Addition of Each of
the Aggregating Agents

AGGREGATING
AGENT

AGGREGATION(%)
DIABETIC
CONTROLS
SUBJECTS

P VALUE*

ADP:

lµM

22 ± 7t
69 ± 4
76 ± 4

80 ± 4 (9):j:
88 ± 4(9)
86 ± 3 (9)

<0.001
<0.005
NS§

lµM
2µM
5µM

39 ± 8
60 ± 6
66 ± 6

82 ± 5 (IO)
85 ± 3(9)
84 ± 2(10)

<0.001
<0.0 1
<0.005

Collagen:
I µg/ ml
2µg/ml
IOµg/ ml

53 ± 10
69 ± 8
77 ± 8

80 ± 3 (8)
84 ± 4 (8)
86±3(8)

< 0.05
NS
<0.05

2µM

5µM
Epinephrine:

* Difference between % aggregation seen in the platelet-rich
plasma obtained from control and that in diabetic subjects.
t Mean± SEM.
:j: Figures in parentheses denote no. of subjects
§ Not significant.

resulting in glomerular ischemia and glomerulosclerosis. There is some further evidence that involves
platelets: thromboglobulin, a protein which is derived
from the platelet, has been found to be increased in
the circulation of those diabetics who have microangiopathy. There are also tests for the presence of
circulating platelet aggregates, and those diabetics
who have the most severe small vessel disease are also
the ones who show the highest levels of these circulating platelet aggregates. A recent study2 reported on
the efficacy of sulfinpyrazone in the prevention of
morbid events in patients who have severe coronary
artery disease. There are active studies in progress to
evaluate antiplatelet drugs in a variety of diseases
that affect blood vessels, particularly coronary artery
disease, atherosclerosis, and different types of renal
disease.
Amyloidosis is always listed as associated with
diabetes mellitus. Certainly the onset of nephrotic
syndrome or heavy proteinuria in a patient with longstanding diabetes does raise the possibility that secondary amyloidosis may be present. With respect to
immunologic factors which crop up in consideration
of almost every type of renal disease, immunoglobulins and complements are found within the
glomerulus of the diabetic kidney. Their presence in a
rather nonspecific pattern together with several other
serum proteins has been interpreted not to represent
a specific immunologic event such as immune complex disease or anti-glomerular basement membrane

(anti-GBM) disease. Still, there are some lines of
evidence which do not exclude completely the idea
that immunologic problems are present in the diabetic and may be contributing to the renal disease. It
was recently reported that juvenile _d iabetes mellitus
can be viewed as a genetic disease transmitted as an
autosomal recessive gene. 3 More interesting, perhaps,
is the close association of the diabetic gene with the
HL-A locus. This area of the chromosome is concerned with a variety of immunologic responses, and
many other diseases which have a close association
with the HL-A locus have been more firmly established as being the result of an immunologic abnormality. Based on this there is still speculation that the
diabetic may have altered immunologic responses
and that this in turn may lead to primary or secondary renal damage.
Drug-induced disease of the kidney, while not confined to the diabetic, may assume increased signficance
for these patients. There have been several reports of
acute renal failure following the use of iodine contrast agents; for the most part, this can be prevented
in the nondiabetic population by avoiding dehy-

40

..,,
I-

w
..J
w

I-

<

..J
~

30

0
0
0

0
0

in

'a:: 20
~
~

e

'cC)

• Diabetic

w

l?
~

10

• Control

0.5 1.0

2.0

3.0

4.0

MINUTES AFTER ADDITION OF ARACHIDONIC ACID
Figure-Time course for the production of iPG E in platelet-rich
plasma (PRP) from exogenous arachidonic acid (0.5mM). The
values are the mean ± SEM for nine subject pairs.
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dration which is part of the preparation of patients
for radiologic examinations. Diabetics, however,
tend to develop acute renal failure with a greater
frequency than nondiabetics; moreover, avoiding dehydration does not seem to be protective. This suggests that something about the diabetic kidney predisposes it to damage in the face of a quantity of
hyperosomotic material. The question arises whether
the diabetic kidney is more susceptible to other nephrotoxic agents such as the aminoglycoside antibiotics
and a host of other medications which have potential
nephrotoxicity. The lack of a definite answer suggests
that in the management of diabetics both diagnostic
and therapeutic agents should be selected for their
reduced incidence of nephrotoxicity.
Several studies have attempted to identify factors of importance in determining the development
and progression of diabetic nephropathy. The data to
be presented were derived from a small number of
patients with biopsy-proven glomerulosclerosis who
were followed for several years at which time a repeat
biopsy was performed.' As far as the type of diabetes
is concerned, of the 11 adult onset diabetics, 9
showed no progression of their glomerulosclerosis,
and 2 became worse. In contrast, of the 6 juvenile
diabetics, l showed no change and 5 showed progression of the disease. With regard to blood glucose
control, 6 of the patients maintained good sugar control for the whole length of the study and none of the
6 showed progression of their glomerulosclerosis. By
contrast, 13 patients were rated to be poorly controlled and IO of them showed a progression of their
renal lesions. In respect to the age of onset of these
diabetics, patients in the group that showed no
change were considerably older at the time of the
onset of their diabetes than were those in the group
that became worse. Obviously these three variables
are not independent since, by and large, in older
patients the adult onset type of diabetes can easily be
managed by diet and weight reduction. But the results do suggest that blood glucose control may be
important in terms of slowing down or averting the
development of glomerulosclerosis.
There appear then to be at least three phases in
the renal disease that accompanies diabetes. The first
is a pre-proteinuria phase. Phase 2 is marked by the
onset of proteinuria, and phase 3 would be development of azotemia. Several groups have tried to study
the question, Is there anything abnormal about the
kidney in the pre-proteinuric phase?, that is, before
proteinuria becomes manifest and at a time when the
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other renal function tests are also normal. 6 If glomerulosclerosis progresses slowly with time, there
might be a gradual increase in the excretion of albumin in the urine as the function of the duration of the
diabetic process until such time as the amount of
albumin in the urine definitely reaches an abnormal
quantity. In a study of 97 young male diabetics who
were followed from 1-19 or more years after the
diagnosis of diabetes, there was no increase in albumin excretion throughout this period of time. Those
who develop proteinuria are clearly distinguished
from those who do not. Because strenuous exercise
increases albumin excretion, a group of 13 juvenile
diabetics were exercised at a rate which had not affected urinary albumin levels in 9 normal controls.
The diabetics showed a statistically significant increase in protein excretion that returned to baseline
after stopping the exercise. Another element that has
been examined is the excretion of low molecular
weight proteins by diabetics; these represent proteins
that are considerably smaller than albumin and are
freely filtered at the glomerulus. Almost none, however, appear in the urine because most of these filtered proteins are reabsorbed by the cells of the proximal tubule . In the pre-proteinuric phase, diabetics
show an increase in excretion of low molecular
weight proteins. These results, together with additional information on albumin excretion, suggest that
the metabolic state of diabetes can adversely affect
renal cell function so that when the diabetic is poorly
controlled, the cells are less able to reabsorb filtered
proteins, including albumin.
In addition to studies on patients, there have
been attempts to gain information about diabetes
through the use of animal models. Diabetes may be
induced in animals either by removing the pancreas
or by destroying the insulin-producing cells with a
chemical such as streptozotocin. These animals then
develop hyperglycemia and over the next several
months their kidneys will show the kind of lesions
that are present in humans: namely, there is an increase in the mesangial matrix and an increase in the
degree of glomerulosclerosis together with deposition
of immunoglobulins and complement. If the kidneys
from a diabetic animal are transplanted into a normal
animal, the diabetic changes rapidly disappear. On
the other hand, if kidneys from a normal animal are
transplanted into a diabetic animal, diabetic changes
will develop. When pancreatic tissue is successfully
transplanted into the diabetic animal, then coincident
with the rise in insulin level, there is striking improve-
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ment in the appearance of the diabetic kidney. This
indicates that the changes seen in the glomerulus are
at least initially reversible and that metabolic control
of blood glucose, or at least the presence of insulin in
appropriate quantities to keep the blood glucose normal, is a contributing factor to the development of
diabetic changes.
The outline for therapy of diabetic kidney disease calls for the best blood glucose control circumstances will permit. Antihypertensive therapy has to
be emphasized together with optimal management of
congestive cardiac failure in order to maintain a high
cardiac output and avoid prerenal azotemia. The patient should be evaluated for obstruction and for
urinary tract infection. Nephrotoxic agents should be
avoided as much as possible. As for vascular complications, anticoagulation offers little value as, by and
large, patients who have renal disease also have retinal disease which is aggravated by these drugs. The
antiplatelet drugs, based on available evidence, are
quite promising, although unproven at the present
time. As far as the treatment of end-stage renal disease in the diabetic is concerned, the same four modalities are open to these patients as anyone else:
living related transplants, cadaver transplants, hemodialysis and peritoneal dialysis . Because of technical
advances, greater experience in dealing with diabetics, and earlier acceptance of diabetics into end-stage
renal failure programs, the prognosis has improved
considerably during the past couple of years.6 Transplantation from a living related donor seems to be as
good in diabetics as in the general population, so that
this would seem to be the treatment of choice for a
diabetic with end-stage renal disease. The results with
cadaver kidney transplantation tend to be poorer
than those of the general population and until we
have some better methods of managing cadaver kidney transplants in general, this is probably the least

promising mode of therapy for the diabetic. Hemodialysis is the treatment that will be applied to the
majority of these people. The problems are in establishing a suitable blood access site because of severe
vascular disease and the requirement for anticoagulation during dialysis which frequently leads to
a deterioration of vision. Many nephrologists now
feel that the treatment of choice if a living related
donor is not available is peritoneal dialysis; the major
problem here is peritonitis as well as the necessity for
using high-glucose containing solutions in the peritoneal cavity which can lead to severe degrees of hyperglycemia, but the complications associated with
bleeding in the eye are avoided and vascular access is
not necessary.
The table and the figure are reproduced with permission from
the New England Journal of Medicine (297:1306-1310, 1977).
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